US Bancorp’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

US Bancorp’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-54,897	Closed	-$14K	–	4206
2023 Q1	$14K	Hold	54,897	–	–	﹤0.01%	3160
2022 Q4	$64.8K	Hold	54,897	–	–	﹤0.01%	2398
2022 Q3	$112K	Buy	+54,897	New	+$93.2K	﹤0.01%	2149

US Bancorp's PEAR Position: Q2 2023 in Review

US Bancorp sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 54,897 shares — an estimated $14K sold.

US Bancorp first reported a position in PEAR in Q3 2022 and held it in 3 quarters. The position peaked at $112K in Q3 2022. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

US Bancorp reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
US Bancorp sold 54,897 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $14K.
US Bancorp first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q3 2022 and held it in 3 quarters.
US Bancorp's Pear Therapeutics, Inc. Class A Common Stock position peaked at $112K in Q3 2022.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on US Bancorp's 13F filing for Q2 2023, filed 10 Aug 2023.